Limits...
Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus

Comparison of weekly influenza incidence for B/Victoria and B/Yamagata predicted by the model versus the weekly incidence observed over the period 2000–2013. Green lines indicate the observed incidence and pink lines indicate the predicted incidence.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4549101&req=5

fig02: Comparison of weekly influenza incidence for B/Victoria and B/Yamagata predicted by the model versus the weekly incidence observed over the period 2000–2013. Green lines indicate the observed incidence and pink lines indicate the predicted incidence.

Mentions: Figure2 shows the match obtained, after calibration, between weekly incidence time series computed by the model and weekly incidence observed over the period 2000–2013. Our calibration process allowed the model to achieve R2 of 95·4% and 93·0% for B/Victoria and B/Yamagata, respectively. Ranges of R0 yearly variations, classically computed15 with beta estimated by the model, are given in Table2 for B/Victoria, B/Yamagata, and for A/H1N1 and A/H3N2 (the absence of epidemic circulation of a particular strain in a given year yields an R0 < 1, which is not shown in the table).


Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Comparison of weekly influenza incidence for B/Victoria and B/Yamagata predicted by the model versus the weekly incidence observed over the period 2000–2013. Green lines indicate the observed incidence and pink lines indicate the predicted incidence.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4549101&req=5

fig02: Comparison of weekly influenza incidence for B/Victoria and B/Yamagata predicted by the model versus the weekly incidence observed over the period 2000–2013. Green lines indicate the observed incidence and pink lines indicate the predicted incidence.
Mentions: Figure2 shows the match obtained, after calibration, between weekly incidence time series computed by the model and weekly incidence observed over the period 2000–2013. Our calibration process allowed the model to achieve R2 of 95·4% and 93·0% for B/Victoria and B/Yamagata, respectively. Ranges of R0 yearly variations, classically computed15 with beta estimated by the model, are given in Table2 for B/Victoria, B/Yamagata, and for A/H1N1 and A/H3N2 (the absence of epidemic circulation of a particular strain in a given year yields an R0 < 1, which is not shown in the table).

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus